Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Cetuximab

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    427 result(s) found for: Cetuximab. Displaying page 1 of 22.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2011-006017-34 Sponsor Protocol Number: CBYL719X2104 Start Date*: 2013-03-05
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A phase Ib dose escalation/randomized phase II, multicenter, open-label study of BYL719 in combination with cetuximab in patients with recurrent or metastatic head and neck squamous cell carcinoma
    Medical condition: Head and Neck Carcinoma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Prematurely Ended) FR (Completed)
    Trial results: View results
    EudraCT Number: 2009-014440-10 Sponsor Protocol Number: EMR200068-006 Start Date*: 2009-12-03
    Sponsor Name:Merck KGaA
    Full Title: A Phase II, Open-label, 1:1 Randomized, Controlled Trial Exploring the Efficacy of EMD 1201081 in Combination with Cetuximab in Second-Line Cetuximab-Naïve Subjects with Recurrent or Metastatic Squ...
    Medical condition: Recurrent/metastatic squamous cell cancer of the head and neck
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004864 10060121 Squamous cell carcinoma of head and neck LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) GB (Prematurely Ended) CZ (Prematurely Ended) HU (Completed) FR (Completed) SK (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2009-014041-81 Sponsor Protocol Number: 2906 Start Date*: 2009-11-13
    Sponsor Name:GOIM GRUPPO ONCOLOGICO MERIDIONALE
    Full Title: Optimal strategy in K-ras wild type metastatic colorectal cancer patients: cetuximab plus FOLFIRI followed by FOLFOX+/- cetuximab (GOIM multicenter program)
    Medical condition: k-ras wild type metastatic colorectal cancer patients
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2008-008282-36 Sponsor Protocol Number: GPICD–CR–0801 Start Date*: 2010-05-07
    Sponsor Name:Grupo de Investigação do Cancro Digestivo
    Full Title: Randomized, open-label phase II study evaluating the safety and efficacy of Cetuximab plus modified FOLFOX - 6 versus modified FOLFOX - 6 alone as 2nd line therapy after progression on the 1st line...
    Medical condition: Colorectal cancer KRAS wild-type
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2022-001527-32 Sponsor Protocol Number: SC105(AURELIO-05) Start Date*: 2022-10-21
    Sponsor Name:SOTIO Biotech AG
    Full Title: A phase 2, open-label, single-arm, multicenter study to evaluate the efficacy and safety of SOT101 in combination with cetuximab in patients with RAS wild-type colorectal cancer (AURELIO-05)
    Medical condition: RAS wild-type colorectal cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) BE (Completed) IT (Prematurely Ended) FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-000459-14 Sponsor Protocol Number: VUB/MedOnc/05-001 Start Date*: 2007-07-02
    Sponsor Name:Oncologisch Centrum, Academisch Ziekenhuis Vrije Universiteit Brussel
    Full Title: A Stratified Phase II Study of Cetuximab (ErbituxTM) for the Treatment of Recurrent Glioblastoma Multiforme / Estudio de fase II estratificado de cetuximab para el tratamiento del glioblastoma mult...
    Medical condition: patients with a recurrent glioblastoma multiforme following preceding surgery, radiation therapy and chemotherapy
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2004-002837-37 Sponsor Protocol Number: CA225-045 Start Date*: 2004-11-11
    Sponsor Name:Merck Farma y Química, S.A.
    Full Title: An exploratory pharmacogenomic study of cetuximab monotherapy in patients with metastatic EGFR-Positive colorectal carcinoma
    Medical condition: Metastatic colorectal carcinoma
    Disease: Version SOC Term Classification Code Term Level
    7.0 10052362 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2006-001742-13 Sponsor Protocol Number: 06_RADIO_56 Start Date*: 2006-10-04
    Sponsor Name:Christie Hospital NHS Trust
    Full Title: Locally Advanced Pancreatic Cancer: Phase II study of cetuximab and 3-D conformal image-guided radiotherapy (PACER Study)
    Medical condition: Adenocarcinoma of the pancreas which is locally advanced/inoperable
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2012-001879-37 Sponsor Protocol Number: ArtscanIII Start Date*: 2013-03-05
    Sponsor Name:Department of Oncology, Skåne University Hospital Lund
    Full Title: A randomized multicenter phase III study of cisplatin plus radiotherapy compared to cetuximab plus radiotherapy in locally advanced head and neck cancer
    Medical condition: Stage III and IV head and neck squamous cell cancer (HNSCC) without radiographic signs of distant metastases aimed for radiotherapy with curative intent
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10071536 Head and neck cancer stage IV PT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10071537 Head and neck cancer stage III PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2006-004639-31 Sponsor Protocol Number: INN06 Start Date*: 2007-01-18
    Sponsor Name:TAKO
    Full Title: Multicenter phase II study evaluating docetaxel, CDDP, and cetuximab as induction regimen prior to surgery in chemonaive patients with NSCLC stage IB, II, and IIIA.
    Medical condition: Neoadjuvant treatment of non-small lung cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-005805-35 Sponsor Protocol Number: ARRAY-818-302 Start Date*: 2016-11-28
    Sponsor Name:Array BioPharma Inc.
    Full Title: A Multicenter, Randomized, Open-label, 3-Arm Phase 3 Study of Encorafenib + Cetuximab Plus or Minus Binimetinib vs. Irinotecan/Cetuximab or Infusional 5-Fluorouracil (5-FU)/Folinic Acid (FA) /Irino...
    Medical condition: BRAF V600E-mutant Metastatic Colorectal Cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029104 Neoplasms benign, malignant and unspecified (incl cysts and polyps) SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) HU (Completed) BE (Completed) AT (Completed) NL (Completed) CZ (Completed) DK (Completed) ES (Ongoing) NO (Completed) DE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2014-001126-15 Sponsor Protocol Number: CRICKET Start Date*: 2014-10-03
    Sponsor Name:G.O.N.O. (Gruppo Oncologico Nord Ovest)
    Full Title: A phase II single-arm study of cetuximab plus irinotecan as rechallenge 3rd-line treatment of kras, nras and braf wild-type irinotecan-pretreated metastatic colorectal cancer patients progressing...
    Medical condition: metastatic colonrectal cancer KRAS, NRAS and BRAF wild type.
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004864 10052362 Metastatic colorectal cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2011-000773-31 Sponsor Protocol Number: E7050-702 Start Date*: 2011-12-20
    Sponsor Name:Eisai Inc.
    Full Title: An Open-Label, Multicenter, Randomized, Phase Ib/II Study of E7050 in Combination with Cetuximab versus Cetuximab Alone in the Treatment of Platinum-Resistant Squamous Cell Carcinoma of the Head an...
    Medical condition: Squamous Cell Carcinoma of the Head and Neck
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10060121 Squamous cell carcinoma of head and neck LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2019-004770-25 Sponsor Protocol Number: D7310C00001 Start Date*: 2020-12-11
    Sponsor Name:AstraZeneca AB
    Full Title: A Phase 3 Randomized, Double-blind, Multicenter, Global Study of Monalizumab or Placebo in Combination with Cetuximab in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head an...
    Medical condition: Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Previously Treated With an Immune Checkpoint Inhibitor
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10067821 Head and neck cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) NL (Completed) GR (Completed) DE (Trial now transitioned) BE (Completed) AT (Completed) BG (Completed) PL (Completed) FR (Completed) PT (Completed) IT (Completed) RO (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2014-000579-20 Sponsor Protocol Number: CINC280X2104 Start Date*: 2014-07-24
    Sponsor Name:Novartis Farmacéutica, S.A.
    Full Title: A phase Ib, open-label, multicenter, dose escalation and expansion study, to evaluate the safety, pharmacokinetics and activity of INC280 in combination with cetuximab in c-MET positive CRC and HNS...
    Medical condition: Head and neck squamous cell carcinoma. Colorectal cancer.
    Disease: Version SOC Term Classification Code Term Level
    17.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10060121 Squamous cell carcinoma of head and neck PT
    17.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10052362 Metastatic colorectal cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Temporarily Halted) IT (Completed) DE (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2014-004299-41 Sponsor Protocol Number: ERMES Start Date*: 2014-12-24
    Sponsor Name:Dipartimento di Scienze Mediche Oncologia Medica Policlinico Gemelli
    Full Title: ERbitux MEtastatic colorectal cancer Strategy Study: A phase III randomized two arm study with FOLFIRI + Cetuximab until disease progression compared to FOLFIRI + Cetuximab for 8 cycles followed by...
    Medical condition: Patients with unresectable RAS and BRAF wild-type metastatic colorectal cancer.
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004864 10052362 Metastatic colorectal cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2021-004593-56 Sponsor Protocol Number: CAVE-2 Start Date*: 2022-05-19
    Sponsor Name:GRUPPO ONCOLOGICO DELL'ITALIA MERIDIONALE
    Full Title: A phase II randomized clinical study of the combination of avelumab plus cetuximab as rechallenge strategy in pre-treated RAS/BRAF wild type metastatic colorectal cancer patients
    Medical condition: Pre-treated RAS/BRAF wild type metastatic colorectal cancer patients.
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10052362 Metastatic colorectal cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2021-002177-25 Sponsor Protocol Number: 19-255-03 Start Date*: 2021-11-08
    Sponsor Name:Nektar Therapeutics
    Full Title: A Phase 1b/2, Open-label, Multicenter, Dose Escalation and Dose Expansion Study of NKTR-255 in Combination with Cetuximab as a Salvage Regimen for Solid Tumors
    Medical condition: Relapsed or refractory (R/R) head and neck squamous cell carcinoma (HNSCC) or colorectal carcinoma (CRC)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10009963 Colon carcinoma recurrent LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10007336 Carcinoma colon recurrent LLT
    22.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10082179 Squamous cell carcinoma of head and neck metastatic LLT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10060121 Squamous cell carcinoma of head and neck PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Prematurely Ended) ES (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2014-002826-11 Sponsor Protocol Number: CWNT974X2102C Start Date*: 2014-12-18
    Sponsor Name:Array BioPharma Inc.
    Full Title: A phase Ib/II multi-center, open label, dose escalation study of WNT974, LGX818 and cetuximab in patients with BRAFV600-mutant metastatic colorectal cancer harboring Wnt pathway mutations
    Medical condition: colorectal cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000005080 10010023 Colorectal neoplasms malignant HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) ES (Completed) NL (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2010-019885-10 Sponsor Protocol Number: Dermatux Start Date*: 2011-01-05
    Sponsor Name:Universitätsmedizin Mainz (vertreten durch den wissenschaftlichen Vorstand)
    Full Title: Non-randomized phase-IV-study to investigate the efficacy of FOLFIRI in combination with cetuximab in the first-line treatment of metastatic colorectal cancer inculding a regular dermal prophylaxis...
    Medical condition: metastatic colorectal cancer (mCRC)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10052362 Metastatic colorectal cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed May 07 08:16:08 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA